The Baloch Liberation Army claimed responsibility for seven attacks across Balochistan under 'Operation Herof 2.0,' targeting security posts, vehicles, and intelligence agents. The group vowed to ...

Discover Inovio Pharmaceuticals' Q1 2025 earnings call insights, including progress on INO-3107's BLA submission, reduced expenses, and groundbreaking ...

On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respirato ...

The National Institute of Allergy and Infectious Diseases (NIAID) plans to initiate phase 1 clinical trial of Capricor's ...

BLA's freedom struggle actions are part of coordinated attacks under Operation Herof 2.0 military exercise during which a total of 78 missions were carried out at 58 locations.

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights ...

Discover how Humacyte, Inc. (HUMA) is advancing with its Symvess commercial launch, overcoming challenges, expanding hospital evaluations, and ...

The BLA has claimed responsibility for a total of 71 "coordinated attacks" at more than 51 locations across Pakistan's Balochistan province as part of its 'Operation Herof' over the last few weeks.

The Balochistan Liberation Army reportedly claimed responsibility for 71 coordinated attacks at over 51 locations across ...

The BLA described Pakistan as a “breeding ground” for global terrorists and urged the international community to declare ...

The FDA will issue a decision on the BLA for RGX-121 by November, which if positive, could make it the first gene therapy for Hunter syndrome.